Eine Diabetes-Injektion mit dreifacher Wirkung senkt nachweislich den Blutzucker und das Körpergewicht

SUBMISSION STATEMENT: A new weekly injection called retatrutide has shown strong results in a phase 3 trial for type 2 diabetes, targeting three gut hormones; GLP-1, GIP, and glucagon, making it more wide-ranging than existing drugs like Ozempic or Mounjaro. Over 40 weeks, the 930 participants on the drug lost more than four times as much weight as those on placebo (11.5–15.3% vs 2.6%) and saw their blood sugar drop more than twice as much, with cholesterol and blood pressure also improving. Side effects were mostly mild and gastrointestinal. Experts welcomed the findings but cautioned that the trial only compared the drug to placebo rather than existing treatments, so its relative effectiveness remains unclear, and that patients will still need support around nutrition and muscle mass. Developer Eli Lilly is continuing further trials.